On December 2, Sanofi signed a memorandum of cooperation with the Beijing Economic and Technological Development Zone, which will invest about 1 billion euros to set up a new manufacturing base. This is another important milestone in Sanofi’s development in China, demonstrating its commitment and confidence in China’s long-term development.
According to the reporter, this will be Sanofi’s fourth manufacturing base in China, creating the company’s largest single investment record in China.The agreement was signed during Sanofi Chairman Frederic Oudea’s first visit to China with his board members since taking office.
“Sanofi is firmly optimistic about the long-term development of the Chinese market,” he said. “The Chinese government’s policy of opening up and encouraging innovation, as well as the favorable business environment for foreign enterprises, inject strong confidence into Sanofi’s deep participation in China’s economic development and the high-quality development of the pharmaceutical industry.”
Sanofi CEO Paul Han said: “The new production site will use high standards of automated production, best-in-class digital integrated management, and sustainable environmental standards to ensure superior production standards, which will further help us strengthen the resilience of our supply chain and more efficiently meet the growing demand of local diabetes patients.
Having been deeply engaged in China for more than 40 years, Sanofi has continued to increase investment in manufacturing in China and build a world-class production and supply network. The newly established Beijing insulin production base, together with the Beijing production base that was just expanded last year, and the production bases in Shenzhen and Hangzhou, will jointly form a high-quality production guarantee for Sanofi in China, and is also an important support for Sanofi to deeply participate in the construction of new quality productivity in China’s pharmaceutical industry.
“With the encouragement of favorable policies at all levels of government, we continue to innovate and upgrade the ‘China Solution’ in China, together with partners from all sides of the Chinese pharmaceutical industry, in order to quickly and efficiently support the huge and complex Chinese medical needs, and make medicine more convenient and accessible while accelerating the introduction of first-of-its-kind and best-of-its-kind products to benefit Chinese patients.” It will fully contribute to the early realization of the Healthy China 2030 goal.” Sanofi Greater China president Shi Wan said.
Related topics
